Genome wide association studies for treatment-related adverse effects of pediatric acute lymphoblastic leukemia.

Abstract

Acute lymphoblastic leukemia (ALL) is the most common pediatric hematological malignancy; notwithstanding the success of ALL therapy, severe adverse drugs effects represent a serious issue in pediatric oncology, because they could be both an additional life threatening condition for ALL patients per se and a reason to therapy delay or discontinuation with important fallouts on final outcome. Cancer treatment-related toxicities have generated a significant need of finding predictive pharmacogenomic markers for the a priori identification of at risk patients. In the era of precision medicine, high throughput genomic screening such as genome wide association studies (GWAS) might provide useful markers to tailor therapy intensity on patients' genetic profile. Furthermore, these findings could be useful in basic research for better understanding the mechanistic and regulatory pathways of the biological functions associated with ALL treatment toxicities. The purpose of this review is to give an overview of high throughput genomic screening of the last 10 years that had investigated the landscape of ALL treatment-associated toxicities. This article is categorized under: Cancer > Genetics/Genomics/Epigenetics.

• Authors: Raffaella Franca, Giulia Zudeh, Marianna Lucafò, Marco Rabusin, Giuliana Decorti, Gabriele Stocco
• Journal: WIREs mechanisms of disease (WIREs Mech Dis) Vol. 13 Issue 3 Pg. e1509 (05 2021) ISSN: 2692-9368 [Electronic] United States
• PMID: 33016644 (Publication Type: Journal Article, Review)
• Copyright: © 2020 Wiley Periodicals LLC.

Topics

• Child
• Genome-Wide Association Study
• Genomics
• Humans
• Pharmacogenetics
• Precision Medicine
• Precursor Cell Lymphoblastic Leukemia-Lymphoma (drug therapy)